Literature DB >> 2448233

Anti-Trichomonas vaginalis monoclonal antibodies inducing complement-dependent cytotoxicity.

N Moav1, E Draghi, A David, D Gold.   

Abstract

Hybridomas producing monoclonal antibodies (mAbs) directed against Trichomonas vaginalis (Tv) have been produced in three fusions using mice immunized with live or killed Tv. The ELISA technique was used to test the binding activity of six out of the 48 mAbs produced. It was found that acetone fixation enhanced the binding activity of the antibodies and revealed hidden antigenic determinants. Thirty percent of the mAbs obtained from splenocytes of mice immunized with live Tv were of the IgG3 subtype. Two mAbs of the IgM and IgG3 subtypes demonstrated complement-fixing capacity. Incubation of these mAbs with live Tv and complement at 37 degrees for 30 min lysed the parasites. The lytic process was complement-dependent since in its absence the antibodies only agglutinated the parasites. The mAbs, when partially purified from ascitic fluids, had the same lytic activity as the native preparation. MAbs of the IgG1 subtype which did not fix complement, bound to Tv but did not lyse it. The lytic activity of the mAbs was not inhibited by cervico-vaginal secretions obtained from 14 women. It is suggested that mAbs could be used for diagnostic as well as for therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2448233      PMCID: PMC1454709     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  A serological study of Trichomonas sp. parasitic in man.

Authors:  H KOTT; S ADLER
Journal:  Trans R Soc Trop Med Hyg       Date:  1961-07       Impact factor: 2.184

3.  Phenotypic variation and diversity among Trichomonas vaginalis isolates and correlation of phenotype with trichomonal virulence determinants.

Authors:  J F Alderete; L Kasmala; E Metcalfe; G E Garza
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

4.  Trichomoniasis.

Authors:  M T Brown
Journal:  Practitioner       Date:  1972-11

5.  Metronidazole-resistant trichomonas vaginalis.

Authors:  D Taylor-Robinson; D A Street
Journal:  Lancet       Date:  1981-11-14       Impact factor: 79.321

6.  Nitroimidazoles in the treatment of trichomoniasis, giardiasis, and amebiasis.

Authors:  J F Rossignol; H Maisonneuve; Y W Cho
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1984-02

7.  Antigen analysis of several pathogenic strains of Trichomonas vaginalis.

Authors:  J F Alderete
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

8.  Rapid assay for immunological detection of Trichomonas vaginalis.

Authors:  R M Watt; A Philip; S M Wos; G J Sam
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

9.  Metronidazole: proven benefits and potential risks.

Authors:  P Goldman
Journal:  Johns Hopkins Med J       Date:  1980-07

10.  Detection and characterization of serum antitrichomonal antibodies in urogenital trichomoniasis.

Authors:  M Cogne; P Brasseur; J J Ballet
Journal:  J Clin Microbiol       Date:  1985-04       Impact factor: 5.948

View more
  3 in total

1.  New concepts in the diagnosis and pathogenesis of Trichomonas vaginalis.

Authors:  R Bhatt; M Abraham; D Petrin; G E Garber
Journal:  Can J Infect Dis       Date:  1996-09

2.  Antibody enhances killing of Tritrichomonas foetus by the alternative bovine complement pathway.

Authors:  M K Aydintug; R W Leid; P R Widders
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

3.  Recombinant α-actinin subunit antigens of Trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis.

Authors:  Yi-Ting Xie; Jiang-Mei Gao; Ya-Ping Wu; Petrus Tang; Geoff Hide; De-Hua Lai; Zhao-Rong Lun
Journal:  Parasit Vectors       Date:  2017-02-16       Impact factor: 3.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.